Paper Details

  1. Home
  2. Paper Details

Adverse effects of dasatinib on glucose-lipid metabolism in patients with chronic myeloid leukaemia in the chronic phase.

Author: HuangXiaojun, JiangQian, LiuJing, YuLu

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This retrospective study compared the onset of hyperglycemia, hypertriglyceridemia, hypercholesterolemia, and hyper-LDL-cholesterolemia in patients receiving dasatinib, nilotinib, or imatinib for chronic myeloid leukemia. Dasatinib and nilotinib were associated with a higher incidence of glucose-lipid metabolism abnormalities compared to imatinib.
Paper Details　
Original Abstract of the Article :
To explore the differences in glucose-lipid metabolism profiles among the 3 TKIs, we designed a retrospective study to compare the onset of hyperglycaemia, hypertriglyceridemia, hypercholesterolemia and hyper-low density lipoprotein (LDL)-cholesterolemia in the patients with normal baseline glucose-...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6879732/

データ提供：米国国立医学図書館（NLM）

Dasatinib's Impact on Glucose-Lipid Metabolism in CML Patients

Chronic myeloid leukemia (CML) is a type of cancer that affects the blood and bone marrow. This study explores the side effects of dasatinib, a tyrosine kinase inhibitor used to treat CML, on glucose-lipid metabolism. This is like discovering that a medication used to treat a desert illness has unintended effects on the camels' metabolism.

What did they find?

The study found that dasatinib was associated with a higher risk of hyperglycemia, hypertriglyceridemia, and hypercholesterolemia compared to other tyrosine kinase inhibitors like imatinib and nilotinib. This is like finding that a camel's diet needs to be carefully adjusted after taking a specific medication to avoid metabolic imbalances.

Importance for CML Treatment

These findings suggest that healthcare providers should carefully monitor glucose-lipid metabolism in CML patients receiving dasatinib therapy. This is like keeping a close eye on a camel's health after it has been treated for a desert illness to ensure its continued well-being. Further research is needed to develop strategies for mitigating these metabolic side effects.

Dr. Camel's Conclusion

This study highlights the importance of considering the potential side effects of medications, even those intended to treat serious conditions. It's like understanding that a desert oasis can sometimes hold hidden dangers. Healthcare providers should be aware of these risks and work with patients to minimize their impact.

Date :
  1. Date Completed 2020-11-09
  2. Date Revised 2022-01-14
Further Info :

Pubmed ID

31772301

DOI: Digital Object Identifier

PMC6879732

Related Literature

Article Analysis
・Effects of dasatinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.